Logo image of CLLS

CELLECTIS - ADR (CLLS) Stock Fundamental Analysis

NASDAQ:CLLS - Nasdaq - US15117K1034 - ADR - Currency: USD

2.98  +0.03 (+1.02%)

Fundamental Rating

3

Taking everything into account, CLLS scores 3 out of 10 in our fundamental rating. CLLS was compared to 551 industry peers in the Biotechnology industry. The financial health of CLLS is average, but there are quite some concerns on its profitability. CLLS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CLLS had negative earnings in the past year.
CLLS had a positive operating cash flow in the past year.
In the past 5 years CLLS always reported negative net income.
In the past 5 years CLLS reported 4 times negative operating cash flow.
CLLS Yearly Net Income VS EBIT VS OCF VS FCFCLLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -14.12%, CLLS belongs to the top of the industry, outperforming 81.67% of the companies in the same industry.
CLLS's Return On Equity of -41.34% is fine compared to the rest of the industry. CLLS outperforms 69.69% of its industry peers.
Industry RankSector Rank
ROA -14.12%
ROE -41.34%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
CLLS Yearly ROA, ROE, ROICCLLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

Looking at the Gross Margin, with a value of 4.64%, CLLS is in the better half of the industry, outperforming 72.23% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for CLLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLLS Yearly Profit, Operating, Gross MarginsCLLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

CLLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLLS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CLLS has more shares outstanding
The debt/assets ratio for CLLS has been reduced compared to a year ago.
CLLS Yearly Shares OutstandingCLLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLLS Yearly Total Debt VS Total AssetsCLLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

CLLS has an Altman-Z score of -0.72. This is a bad value and indicates that CLLS is not financially healthy and even has some risk of bankruptcy.
CLLS's Altman-Z score of -0.72 is fine compared to the rest of the industry. CLLS outperforms 60.44% of its industry peers.
CLLS has a debt to FCF ratio of 4.88. This is a neutral value as CLLS would need 4.88 years to pay back of all of its debts.
The Debt to FCF ratio of CLLS (4.88) is better than 92.92% of its industry peers.
A Debt/Equity ratio of 0.65 indicates that CLLS is somewhat dependend on debt financing.
CLLS has a worse Debt to Equity ratio (0.65) than 74.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.88
Altman-Z -0.72
ROIC/WACCN/A
WACC6.35%
CLLS Yearly LT Debt VS Equity VS FCFCLLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 1.73 indicates that CLLS should not have too much problems paying its short term obligations.
The Current ratio of CLLS (1.73) is worse than 79.31% of its industry peers.
A Quick Ratio of 1.73 indicates that CLLS should not have too much problems paying its short term obligations.
CLLS's Quick ratio of 1.73 is on the low side compared to the rest of the industry. CLLS is outperformed by 78.40% of its industry peers.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.73
CLLS Yearly Current Assets VS Current LiabilitesCLLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

CLLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.54%, which is quite impressive.
The Revenue has grown by 357.43% in the past year. This is a very strong growth!
CLLS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.44% yearly.
EPS 1Y (TTM)45.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325%
Revenue 1Y (TTM)357.43%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%85.12%

3.2 Future

The Earnings Per Share is expected to decrease by -75.28% on average over the next years. This is quite bad
The Revenue is expected to grow by 30.02% on average over the next years. This is a very strong growth
EPS Next Y-235.09%
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%
EPS Next 5YN/A
Revenue Next Year1.53%
Revenue Next 2Y3.2%
Revenue Next 3Y12.51%
Revenue Next 5Y30.02%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLLS Yearly Revenue VS EstimatesCLLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
CLLS Yearly EPS VS EstimatesCLLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CLLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLLS Price Earnings VS Forward Price EarningsCLLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CLLS is valued cheaper than 95.10% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.62
EV/EBITDA N/A
CLLS Per share dataCLLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

CLLS's earnings are expected to decrease with -75.28% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTIS - ADR

NASDAQ:CLLS (8/4/2025, 1:48:19 PM)

2.98

+0.03 (+1.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners18.59%
Inst Owner Change0%
Ins Owners2.82%
Ins Owner ChangeN/A
Market Cap298.97M
Analysts84.62
Price Target7.87 (164.09%)
Short Float %0.5%
Short Ratio1.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)82%
Min EPS beat(2)18.3%
Max EPS beat(2)145.69%
EPS beat(4)4
Avg EPS beat(4)73.41%
Min EPS beat(4)6.42%
Max EPS beat(4)145.69%
EPS beat(8)6
Avg EPS beat(8)27.22%
EPS beat(12)9
Avg EPS beat(12)23.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)108.7%
Min Revenue beat(2)55.84%
Max Revenue beat(2)161.56%
Revenue beat(4)4
Avg Revenue beat(4)91.56%
Min Revenue beat(4)50.31%
Max Revenue beat(4)161.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.6%
PT rev (3m)8.12%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.13%
EPS NY rev (1m)0%
EPS NY rev (3m)0.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-37.71%
Revenue NY rev (3m)-37.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.05
P/FCF 15.62
P/OCF 13
P/B 2.28
P/tB 2.3
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)0.19
FCFY6.4%
OCF(TTM)0.23
OCFY7.69%
SpS0.74
BVpS1.31
TBVpS1.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.12%
ROE -41.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.64%
FCFM 25.96%
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 4.88
Debt/EBITDA N/A
Cap/Depr 19.36%
Cap/Sales 5.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.73
Altman-Z -0.72
F-Score7
WACC6.35%
ROIC/WACCN/A
Cap/Depr(3y)12.8%
Cap/Depr(5y)139.39%
Cap/Sales(3y)9.66%
Cap/Sales(5y)33.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325%
EPS Next Y-235.09%
EPS Next 2Y-58.04%
EPS Next 3Y-75.28%
EPS Next 5YN/A
Revenue 1Y (TTM)357.43%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%85.12%
Revenue Next Year1.53%
Revenue Next 2Y3.2%
Revenue Next 3Y12.51%
Revenue Next 5Y30.02%
EBIT growth 1Y35.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.14%
EBIT Next 3Y-33.24%
EBIT Next 5Y-29.24%
FCF growth 1Y174.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y192.9%
OCF growth 3YN/A
OCF growth 5YN/A